Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Moleculin Biotech reported Q1 2026 results with $0 revenue and a net loss of $12.8 million ($3.54 per share), driven by $5.4 million in R&D expenses. The company holds $10.3 million in cash, which management believes will fund operations into the third quarter of 2026, necessitating further financing.
Key figures
- Revenue
- 0
- Cr rate
- 40%
- Ga expenses
- 2496000
- Rd expenses
- 5378000
- Enrolled subjects
- 45
- Financing proceeds
- 8300000
- Weighted avg shares
- 4124482
- Cash and equivalents
- 10317000
- Total operating expenses
- 7874000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.